Switch theme
Sign up to access all valuation multiples
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
2004
73
LTM Revenue $26.6M
LTM EBITDA -$73.2M
$1.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mesoblast has a last 12-month revenue (LTM) of $26.6M and a last 12-month EBITDA of -$73.2M.
In the most recent fiscal year, Mesoblast achieved revenue of $3.8M and an EBITDA of -$40.4M.
Mesoblast expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mesoblast valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $26.6M | XXX | $3.8M | XXX | XXX | XXX |
| Gross Profit | $24.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 90% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$73.2M | XXX | -$40.4M | XXX | XXX | XXX |
| EBITDA Margin | -275% | XXX | -1064% | XXX | XXX | XXX |
| EBIT | -$91.9M | XXX | -$37.2M | XXX | XXX | XXX |
| EBIT Margin | -345% | XXX | -982% | XXX | XXX | XXX |
| Net Profit | -$111M | XXX | -$56.5M | XXX | XXX | XXX |
| Net Margin | -415% | XXX | -1490% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $33.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Mesoblast's stock price is AUD 2 (or $1).
Mesoblast has current market cap of AUD 2.2B (or $1.4B), and EV of AUD 2.3B (or $1.5B).
See Mesoblast trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5B | $1.4B | XXX | XXX | XXX | XXX | $-0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Mesoblast has market cap of $1.4B and EV of $1.5B.
Mesoblast's trades at 134.5x EV/Revenue multiple, and -33.9x EV/EBITDA.
Equity research analysts estimate Mesoblast's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mesoblast has a P/E ratio of -19.5x.
See valuation multiples for Mesoblast and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV/Revenue | 86.2x | XXX | 134.5x | XXX | XXX | XXX |
| EV/EBITDA | -31.4x | XXX | -33.9x | XXX | XXX | XXX |
| EV/EBIT | -25.0x | XXX | -30.8x | XXX | XXX | XXX |
| EV/Gross Profit | 95.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -19.5x | XXX | -21.9x | XXX | XXX | XXX |
| EV/FCF | -20.5x | XXX | -28.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMesoblast's last 12 month revenue growth is 335%
Mesoblast's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.6M for the same period.
Mesoblast's rule of 40 is -571% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Mesoblast's rule of X is 562% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Mesoblast and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 335% | XXX | 299% | XXX | XXX | XXX |
| EBITDA Margin | -275% | XXX | -397% | XXX | XXX | XXX |
| EBITDA Growth | -61% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -571% | XXX | -62% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 562% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 266% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 430% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1082% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Orthocell | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mesoblast acquired XXX companies to date.
Last acquisition by Mesoblast was XXXXXXXX, XXXXX XXXXX XXXXXX . Mesoblast acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Mesoblast founded? | Mesoblast was founded in 2004. |
| Where is Mesoblast headquartered? | Mesoblast is headquartered in Australia. |
| How many employees does Mesoblast have? | As of today, Mesoblast has 73 employees. |
| Who is the CEO of Mesoblast? | Mesoblast's CEO is Dr. Silviu Itescu, F.A.C.P.,F.R.A.C.P.. |
| Is Mesoblast publicy listed? | Yes, Mesoblast is a public company listed on ASX. |
| What is the stock symbol of Mesoblast? | Mesoblast trades under MSB ticker. |
| When did Mesoblast go public? | Mesoblast went public in 2004. |
| Who are competitors of Mesoblast? | Similar companies to Mesoblast include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Mesoblast? | Mesoblast's current market cap is $1.4B |
| What is the current revenue of Mesoblast? | Mesoblast's last 12 months revenue is $26.6M. |
| What is the current revenue growth of Mesoblast? | Mesoblast revenue growth (NTM/LTM) is 335%. |
| What is the current EV/Revenue multiple of Mesoblast? | Current revenue multiple of Mesoblast is 86.2x. |
| Is Mesoblast profitable? | Yes, Mesoblast is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Mesoblast? | Mesoblast's last 12 months EBITDA is -$73.2M. |
| What is Mesoblast's EBITDA margin? | Mesoblast's last 12 months EBITDA margin is -275%. |
| What is the current EV/EBITDA multiple of Mesoblast? | Current EBITDA multiple of Mesoblast is -31.4x. |
| What is the current FCF of Mesoblast? | Mesoblast's last 12 months FCF is -$112M. |
| What is Mesoblast's FCF margin? | Mesoblast's last 12 months FCF margin is -421%. |
| What is the current EV/FCF multiple of Mesoblast? | Current FCF multiple of Mesoblast is -20.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
